Patient Outcomes and Cost Effects of Medicaid Formulary Restrictions on Antidepressants

Seth Seabury, Darius Lakdawalla, Walter Deborah, Hayes John, Gustafson Thomas, Shrestha Anshu and Dana Goldman
Additional contact information
Walter Deborah: Takeda Pharmaceuticals America, Inc., Washington, DC, USA
Hayes John: National Network of Depression Centers, Ann Arbor, MI, USA
Gustafson Thomas: Arnold and Porter, LLP, Washington, DC, USA
Shrestha Anshu: Precision Health Economics, Los Angeles, CA, USA

Forum for Health Economics & Policy, 2014, vol. 17, issue 2, 153-168

Abstract: Many state Medicaid programs have implemented policies designed to reduce spending on prescription drugs by restricting access to branded products. For patients with major depressive disorder, formulary restrictions could severely limit access to antidepressant therapies and disrupt care. We linked data on patient outcomes and spending from 24 state Medicaid programs to information on formulary restrictions from 2001 to 2008. Outcomes included frequency of MDD-related hospitalizations and ER visits per patient and total healthcare spending. We estimated the effect of the policies on patient outcomes and spending using a difference-and-difference approach. We found that restricting access to antidepressants increased the probability of an MDD-related hospitalization by 1.7 percentage points (16.6%). Furthermore, we found no evidence that these restrictions resulted in any net savings for Medicaid.

Keywords: depression; Medicaid; prescription drug coverage (search for similar items in EconPapers)
Date: 2014
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://doi.org/10.1515/fhep-2014-0016 (text/html)
For access to full text, subscription to the journal or payment for the individual article is required.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bpj:fhecpo:v:17:y:2014:i:2:p:16:n:4

Ordering information: This journal article can be ordered from
https://www.degruyter.com/journal/key/fhep/html

DOI: 10.1515/fhep-2014-0016

Access Statistics for this article

Forum for Health Economics & Policy is currently edited by Dana Goldman

More articles in Forum for Health Economics & Policy from De Gruyter
Bibliographic data for series maintained by Peter Golla ().